A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.
An examination of how the astronomically deadly and expensive opioid epidemic has generated significant litigation risk for healthcare businesses.
In light of breaking news, the pharma value chain is definitely ripe for disruption. Here's how health plans, employers, and drug companies can adjust to the new normal.
_145x171.jpg)
The election results sent biopharma stock soaring. Breaking down what’s really on tap for biopharma over the next four years.
Through this series of infographics, learn how payers, providers, and life sciences companies will be impacted by our 45th president.
